CY1109959T1 - Αννεξινη v για αποτροπη ρηξης αθηροσκληρωτικων πλακων - Google Patents

Αννεξινη v για αποτροπη ρηξης αθηροσκληρωτικων πλακων

Info

Publication number
CY1109959T1
CY1109959T1 CY20101100324T CY101100324T CY1109959T1 CY 1109959 T1 CY1109959 T1 CY 1109959T1 CY 20101100324 T CY20101100324 T CY 20101100324T CY 101100324 T CY101100324 T CY 101100324T CY 1109959 T1 CY1109959 T1 CY 1109959T1
Authority
CY
Cyprus
Prior art keywords
annexin
binding
immunoglobulins
atherosclerosis
atherothrombosis
Prior art date
Application number
CY20101100324T
Other languages
English (en)
Inventor
Anna Frostegård
Johan Frostegård
Original Assignee
Athera Biotechnologies Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Athera Biotechnologies Ab filed Critical Athera Biotechnologies Ab
Publication of CY1109959T1 publication Critical patent/CY1109959T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Escalators And Moving Walkways (AREA)
  • Cosmetics (AREA)

Abstract

Η αρτηριοσκλήρυνση μπορεί να θεωρηθεί ως απόκριση σε κάκωση και δεν είναι αυτή καθαυτή η αρτηριοσκλήρυνση που είναι επικίνδυνη αλλά άλλοι παράγοντες που οδηγούν σε ρήξη αθηροσκληρωτικών πλακών. Στην παρούσα εφεύρεση ταυτοποιήσαμε τέτοιους παράγοντες. Μειωμένη δέσμευση αννεξίνης V στο ενδοθήλιο παρατηρήθηκε σε ασθενείς με ιστορικό αθηροθρόμβωσης. Η χρήση φυσικής αννεξίνης V ή αμινοτελικού θραύσματος ως ενεργό συστατικό ή υποκλάσμα ανοσοσφαιρινών για παρασκευή φαρμακευτικής σύνθεσης προτείνεται για βελτίωση αυτής της δέσμευσης. Η χρήση αννεξίνης V, αμινοτελικών θραυσμάτων ή ανοσοσφαιρινών για να αυξηθεί η δέσμευση αννεξίνης V σε καρωτιδικές αθηροσκληρωτικές πλάκες αντιπροσωπεύει πρωτότυπο μηχανισμό για αποτροπή αθηροθρόμβωσης.
CY20101100324T 2004-04-15 2010-04-09 Αννεξινη v για αποτροπη ρηξης αθηροσκληρωτικων πλακων CY1109959T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52138504P 2004-04-15 2004-04-15
EP05735990A EP1755642B1 (en) 2004-04-15 2005-04-15 Annexin v for preventing plaque rupture

Publications (1)

Publication Number Publication Date
CY1109959T1 true CY1109959T1 (el) 2014-09-10

Family

ID=34966761

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100324T CY1109959T1 (el) 2004-04-15 2010-04-09 Αννεξινη v για αποτροπη ρηξης αθηροσκληρωτικων πλακων

Country Status (15)

Country Link
US (1) US20080044404A1 (el)
EP (1) EP1755642B1 (el)
JP (2) JP2007532617A (el)
CN (1) CN1997385B (el)
AT (1) ATE454898T1 (el)
AU (1) AU2005232436C1 (el)
CA (1) CA2563408C (el)
CY (1) CY1109959T1 (el)
DE (1) DE602005018914D1 (el)
DK (1) DK1755642T3 (el)
ES (1) ES2356364T3 (el)
PL (1) PL1755642T3 (el)
PT (1) PT1755642E (el)
SI (1) SI1755642T1 (el)
WO (1) WO2005099744A1 (el)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7645739B2 (en) 2001-02-21 2010-01-12 Alavita Pharmaceuticals, Inc. Modified annexin compositions and methods of using same
JP2011506590A (ja) 2007-12-18 2011-03-03 アセラ・バイオテクノロジーズ・アーベー 血管疾患を治療するための化合物および方法
HUE035034T2 (en) * 2008-02-22 2018-05-02 Annexin Pharmaceuticals Ab Compounds and methods for preventing or treating restenosis
EP2350112A4 (en) 2008-10-03 2013-01-16 Advanced Proteome Therapeutics Inc Site specific N-termin protein modifications and conjugate formation
US9192649B2 (en) 2008-10-17 2015-11-24 London Health Sciences Centre Research Inc. Annexin and its use to treat inflammatory disorders
WO2010069605A2 (en) * 2008-12-19 2010-06-24 Medirista Biotechnologies Ab Oxidized cardiolipin as a novel pro-inflammatory factor
WO2011160845A2 (en) 2010-06-24 2011-12-29 Medirista Biotechnologies Ab Oxidized phospholipids and lipoproteins, and antibodies thereto, as biomarkers of inflammatory conditions and methods of treatment
CN102690345B (zh) * 2011-03-24 2014-03-19 江苏靶标生物医药研究所有限公司 人膜联蛋白v变体及其表达、制备和应用
WO2012136819A1 (en) 2011-04-05 2012-10-11 Athera Biotechnologies Ab Therapeutic and prophylactic methods, uses and compositions comprising anexin a5
WO2013109144A1 (en) * 2012-01-18 2013-07-25 Stichting Katholieke Universiteit Annexin a5 snp in atherosclerosis
GB2552853B (en) * 2015-09-17 2018-11-21 Annexin Pharmaceuticals Ab Purification of Annexin A5 from a composition that includes a calcium ion chelator
GB2542391A (en) 2015-09-17 2017-03-22 Annexin Pharmaceuticals Ab Process of manufacture
GB2552724B (en) * 2015-09-17 2020-05-06 Annexin Pharmaceuticals Ab Purification of Annexin A5 by anion exchange and affinity chromatography
CN105327042A (zh) * 2015-12-16 2016-02-17 刘爱玲 一种治疗颈动脉斑块的中药药膏及制备方法
GB201702144D0 (en) 2017-02-09 2017-03-29 Annexin Pharmaceuticals Ab Therapeutic compositions
CN108159421B (zh) * 2018-02-05 2021-05-18 苏州大学 磷脂酰丝氨酸阻断剂在制备治疗血小板数量减少相关疾病药物中的用途
TW202146042A (zh) * 2020-03-06 2021-12-16 瑞典商阿斯特捷利康公司 用於治療動脈和靜脈血栓形成的協同且靶向的組成物
EP4355765A2 (en) 2021-06-14 2024-04-24 Institut National de la Santé et de la Recherche Médicale (INSERM) Mutated annexin a5 polypeptides and uses thereof for therapeutic purposes
WO2023143463A1 (en) * 2022-01-30 2023-08-03 Nanjing Reju Therapeutics , Inc. Fusion protein and application thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5632986A (en) * 1991-05-09 1997-05-27 The University Of Washington Phospholipid-targeted thrombolytic agents
US5968477A (en) * 1994-01-24 1999-10-19 Neorx Corporation Radiolabeled annexin conjugates with hexose and a chelator
WO1996015152A1 (fr) * 1994-11-11 1996-05-23 International Reagents Corporation Anticorps monoclonal antiannexine-v, procede pour produire cet anticorps, et utilisation de cet anticorps
WO1999002992A1 (en) * 1997-07-11 1999-01-21 The Mount Sinai School Of Medicine Of The City University Of New York Assays for diagnosis of thrombophilic disease
US5932712A (en) * 1997-07-31 1999-08-03 Incyte Pharmaceuticals, Inc. Annexin binding protein
US6228360B1 (en) * 1998-08-19 2001-05-08 Ajinomoto Co., Inc. Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody
CA2382676A1 (en) * 1999-11-05 2001-05-17 Warner-Lambert Company Prevention of plaque rupture by acat inhibitors
GB0005867D0 (en) * 2000-03-10 2000-05-03 Medinnova Sf Method
WO2001066124A2 (en) * 2000-03-10 2001-09-13 Medinnova Sf Composition for the treatment of heart failure
DE60134009D1 (de) * 2000-05-05 2008-06-26 Inst Nat Sante Rech Med Verwendung von il-18 inhibitoren zur behandlung und/oder prävention von atherosklerose
IL135993A0 (en) * 2000-05-05 2001-05-20 Omrix Biopharmaceuticals Pharmaceutical composition for the treatment of fibrosis
ATE359807T1 (de) * 2001-02-21 2007-05-15 Surromed Inc Modifizierte annexin-proteine und verhinderung und behandlung von thrombose
US20050013778A1 (en) * 2001-04-03 2005-01-20 Theseus Imaging Corporation Methods and compositions for predicting the response to a therapeutic regimen in a subject having a disease associated with cell death
US20040203083A1 (en) * 2001-04-13 2004-10-14 Biosite, Inc. Use of thrombus precursor protein and monocyte chemoattractant protein as diagnostic and prognostic indicators in vascular diseases
JP3806694B2 (ja) * 2001-05-04 2006-08-09 バイオサイト インコーポレイテッド 急性冠状動脈症候群の診断マーカーおよびその使用方法
US20030152513A1 (en) * 2001-09-06 2003-08-14 Imetrix, Inc. Intravascular delivery of therapeutic and imaging agents to stressed and apoptotic cells using annexin V as a targeting vector
US20040042959A1 (en) * 2002-08-28 2004-03-04 Michael Montalto Imaging cell death in vivo using non-radionuclide contrast agents

Also Published As

Publication number Publication date
SI1755642T1 (sl) 2010-05-31
US20080044404A1 (en) 2008-02-21
CN1997385A (zh) 2007-07-11
PL1755642T3 (pl) 2010-06-30
ES2356364T3 (es) 2011-04-07
JP2012136536A (ja) 2012-07-19
WO2005099744A1 (en) 2005-10-27
EP1755642A1 (en) 2007-02-28
CN1997385B (zh) 2012-01-11
AU2005232436A1 (en) 2005-10-27
PT1755642E (pt) 2010-04-20
CA2563408C (en) 2015-08-25
AU2005232436C1 (en) 2010-08-26
AU2005232436B2 (en) 2010-03-11
DK1755642T3 (da) 2010-05-10
DE602005018914D1 (de) 2010-03-04
EP1755642B1 (en) 2010-01-13
ATE454898T1 (de) 2010-01-15
CA2563408A1 (en) 2005-10-27
JP2007532617A (ja) 2007-11-15

Similar Documents

Publication Publication Date Title
CY1109959T1 (el) Αννεξινη v για αποτροπη ρηξης αθηροσκληρωτικων πλακων
PH12015500576A1 (en) Anti-notch3 agonist antibodies and their use in the treatment of notch3-related diseases
CR9994A (es) Vacuna terapéutica
CY1115808T1 (el) Ενδιαμεσα για την παρασκευη δισθενων μιμητικων toυ smac
MA32397B1 (fr) Agonistes mixtes basés sur gip destinés au traitement de troubles métaboliques et de l'obésité
CL2013000304A1 (es) Compuestos derivados de 2-arilamino-bencimidazoles inhibidores de prostaglandina e2 (mpges-1); composicion farmaceutica que los comprende; compuestos intermediarios; uso en el tratamiento de enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor.
BRPI0515316A (pt) compostos de imidazoquinolina
AR054428A1 (es) Composiciones de anticuerpos anti factor estimulante de colonia de macrofagos (anti-m-csf) que tienen menores niveles de endotoxina
DK1377280T3 (da) Fyldmidler som mæthedsfornemmelsesgivende midler
CL2012001043A1 (es) Compuestos derivados de hexahidroindenopiridina y/o octahidrobenzoquinolina, inhibidores de 11ß-hidroxiesteroide deshidrogenasa 1 (hsd 1); composiciones farmaceuticas que comprenden a los compuestos; y uso de los compuestos para la preparacion de medicamentos para el tratamiento de trastornos metabolicos.
MX2009000285A (es) Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
AR058753A1 (es) Uso de composiciones nutricionales con fosfolipidos esfingolipidos y colesterol
UY31530A (es) "poliaminas reticuladas y sus usos en composiciones farmacéuticas"
MX2007010560A (es) Roflumilast para el tratamiento de diabetes mellitus.
CL2011002548A1 (es) Compuestos derivados de resolviina; composicion farmaceutica; uso de la composicion; kit farmaceutico; combinacion farmaceutica; uso de los compuestos en el tratamiento y/o prevencion de una condicion oftalmica.
BRPI0816784A8 (pt) Fatores neuro-endócrinos para o tratamento de doenças degenerativas
HK1124863A1 (en) Inhibitors of sodium glucose co-transporter 2 and methods of their use
CO6700879A2 (es) Inhibidores de apoptosis y usos de los mismos
TW200730190A (en) New combination to treat liver fibrosis
ATE518546T1 (de) Zusammensetzungen enthaltend myelin-basisches protein peptiden und medizinische verwendungen
CL2012001940A1 (es) Composiciones que comprenden extractos de andrographis paniculata combinados con extractos de ginkgo biloba complejados con fosfolípidos; y su uso en la preparación de un medicamento para el tratamiento de alzheimer y esclerosis múltiple.
EP2010164A4 (en) COMPOSITIONS COMPRISING S-NITROSOTHIOLS FOR TREATING HEPATIC STEATOSES, OBESITY AND OTHER MATABOLIC SYNCHROME-RELATED DISEASES AND USE THEREOF
CR9200A (es) Uso de un agonista 5-ht6 para el tratamiento y la prevencion de trastornos neurodegenerativos
WO2011011706A3 (en) Methods and compositions for treating or preventing autoimmune diseases using immunomodulatory agents
PA8571901A1 (es) Nueva composicion farmaceutica